Telix ProstACT Phase 3 Study Shows Positive Safety Results
Melbourne, Australia & Indianapolis, United States – March 10, 2026 Telix Pharmaceuticals has announced that Part 1 of the...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
Melbourne, Australia & Indianapolis, United States – March 10, 2026 Telix Pharmaceuticals has announced that Part 1 of the...
TAIPEI, August 28, 2025 — Foresee Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the...
